A Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-controlled Phase II Trial of TTYP01 Tablets in Adolescents and Children With Autism Spectrum Disorders
Latest Information Update: 14 Jan 2025
Price :
$35 *
At a glance
- Drugs Edaravone (Primary)
- Indications Pervasive child development disorders
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Suzhou Auzone Biological Technology
- 08 Jan 2025 Planned initiation date changed from 27 Dec 2024 to 7 Jan 2025.
- 08 Jan 2025 Status changed from not yet recruiting to recruiting.
- 07 Jan 2025 New trial record